RECRUITING

Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The current study is a case control study involving comparisons of tissue interstitial fluid from breast cancer and adjacent non-cancerous tissue as well as that from benign breast lesion and its adjacent non-diseased tissue for a distinguishable breast cancer profile. The purpose of this research is to collect fresh breast nodule/cancer and surrounding non-cancerous tissue for proteomic studies of the interstitial fluid to identify a profile distinguishing breast cancer which will also permit future research on stored interstitial fluid, blood or tissue samples. Specific markers identified from interstitial fluid study will be investigated in blood samples to develop serum markers for breast cancer diagnosis and prognosis. Additionally, we will perform both prospective and retrospective research on breast cancer involving clinical, demographic, epidemiologic information, treatment, follow-up and outcomes on breast nodule/cancer cases collected.

Official Title

Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum

Quick Facts

Study Start:2010-02-03
Study Completion:2028-04
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01042548

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All subjects ≥ 18 years of age undergoing surgery for indeterminate breast nodules, breast tissue reduction, prophylactic mastectomy, and all subjects with newly diagnosed invasive breast cancer will be eligible to participate. If invasive breast cancer or suspicion of invasive breast cancer, target lesion must measure ≥ 1.0 cm on breast imaging before core biopsy.
  1. * Anyone \< 18 years of age.
  2. * Multiple synchronous primary malignancies from different organ systems.

Contacts and Locations

Study Contact

Laura Chiesa
CONTACT
412-831-1320
powersl2@upmc.edu
Min Sun, MD, PhD
CONTACT
412-781-3744
sunxmx@UPMC.EDU

Study Locations (Sites)

UPMC St. Margaret
Pittsburgh, Pennsylvania, 15215
United States

Collaborators and Investigators

Sponsor: University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2010-02-03
Study Completion Date2028-04

Study Record Updates

Study Start Date2010-02-03
Study Completion Date2028-04

Terms related to this study

Keywords Provided by Researchers

  • Proteomics
  • Breast Cancer Markers
  • Tissue Interstitial Fluid

Additional Relevant MeSH Terms

  • Breast Cancer